<DOC>
	<DOCNO>NCT01556490</DOCNO>
	<brief_summary>The safety effectiveness TheraSphere evaluate patient unresectable hepatocellular carcinoma treatment standard-of-care sorafenib plan . All patient receive standard-of-care sorafenib without addition TheraSphere .</brief_summary>
	<brief_title>Efficacy Evaluation TheraSphere Patients With Inoperable Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Signed informed consent prior studyrelated evaluation Male female patient 18 year age Unresectable HCC confirm histology noninvasive AASLD criterion Measurable disease define least one unidimensional measurable lesion CT MRI accord RECIST 1.1 Child Pugh score ≤ 7 point ECOG Performance Status score ≤ 1 Life expectancy 12 week Eligible receive standardofcare sorafenib Platelet count &gt; 50 x 10⁹ &gt; 50 % prothrombin activity Hemoglobin ≥ 8.5 g/dL Bilirubin ≤ 2.5 mg/dL ALT AST &lt; 5 X upper limit normal Amylase lipase ≤ 2X upper limit normal Serum creatinine ≤ 1.5 X upper limit normal INR &lt; 2.0 Main portal vein thrombosis Eligible curative treatment ( ablation transplantation ) History previous concurrent cancer HCC unless treat curatively 5 year prior entry Confirmed presence extrahepatic disease except lung nodule mesenteric portal lymph node ≤ 2.0 cm Risk hepatic renal failure Tumor replacement &gt; 70 % total liver volume base visual estimation investigator OR tumor replacement &gt; 50 % total liver volume presence albumin &lt; 3 mg/dL History severe allergy intolerance contrast agent , narcotic sedative atropine manage medically Contraindications angiography selective visceral catheterization Known contraindication sorafenib include allergic reaction , pillswallowing difficulty , evidence severe systemic disease , uncontrolled hypertension history cardiac arrhythmia ( require antiarrhythmic therapy pace maker ) , congestive heart failure . New York Heart Association class 2 , myocardial infarct within 6 month , prolong QT/QTc &gt; 450ms , laboratory find view investigator make undesirable patient participate trial , significant GI bleed within 30 day , metastatic brain disease , renal failure require dialysis Taking follow : Rifampicin , St. John 's Wort , phenytoin , carbamazepine , phenobarbital , dexamethasone Taking systemic anticancer agent ( docetaxel , doxorubicin , irinotecan ) Taking substrate agent CYP 2B6 ( bupropion , cyclophosphamide , efavirenz , ifosfamide , methadone , paclitaxel , amodiaquine , repaglinide ) Taking UGT 1A1 UGT 1A9 substrate ( e.g . irinotecan ) Taking PGp substrate ( e.g . Digoxin ) Prior liver resection must take &gt; 2 month prior randomization Treatment locoregional therapy ( study treatment ) plan duration clinical study period Prior external beam radiation treatment liver abdomen Prior yttrium90 microsphere treatment liver Prior treatment transarterial chemoembolization ( TACE ) bland embolization &gt; 2 month prior randomization must apply treatment field and/or lobe target treatment protocol Anticancer therapy treatment investigational agent within 30 day prior randomization Adverse effect due prior therapy unresolved randomization Prior systemic treatment treatment HCC , include sorafenib Evidence pulmonary insufficiency clinically evident chronic obstructive pulmonary disease Intervention , compromise , Ampulla Vater Clinically evident ascites ( trace ascites image acceptable ) Pregnancy breast feed Women childbearing potential must negative serum pregnancy test within 14 day prior randomization Disease condition would preclude safe use TheraSphere , include concurrent dialysis treatment , unresolved serious infection include patient know HIV positive Participation concurrent clinical trial evaluate treatment intervention ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>